Literature DB >> 14692720

A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors.

H Richly1, P Kupsch, K Passage, M Grubert, R A Hilger, S Kredtke, D Voliotis, M E Scheulen, S Seeber, D Strumberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14692720     DOI： 10.5414/cpp41620

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN： 0946-1965            Impact factor:   1.366


× No keyword cloud information.
  4 in total

Review 1.  Melanoma genetics and the development of rational therapeutics.

Authors:  Yakov Chudnovsky; Paul A Khavari; Amy E Adams
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

Review 2.  Sorafenib: in advanced renal cancer.

Authors:  Kate McKeage; Antona J Wagstaff
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Targeting the tumor microenvironment: focus on angiogenesis.

Authors:  Fengjuan Fan; Alexander Schimming; Dirk Jaeger; Klaus Podar
Journal:  J Oncol       Date:  2011-08-24       Impact factor: 4.375

Review 4.  Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.

Authors:  Matteo Morotti; Prashanth Hari Dass; Adrian L Harris; Simon Lord
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-04       Impact factor: 2.441
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.